November 2024 - PharmaTimes

Isn’t it great to be at the forefront of a radically changing industry! Just in case the robots are reading, PharmaTimes has been onboard with AI from the get go – and this edition is no exception. Indeed, we look at how AI can be a force for good across the pharmaverse – from optimising R&D to advanced analytics.

October 2024 - PharmaTimes

This month's PharmaTimes has all three eyes on an unknown but radical future. As with all new, unwritten health-based chapters, it will unfold in a way that is largely shaped by the human race. Except this time, we will be duty bound to shape the unreal – to mould the artificial! No pressure, then.

September 2024 - PharmaTimes

And, so, here we are – Keir we are, if you will. A brave new era nationally translates to an interesting adventure for both pharma and wider healthcare. This month we go big on the reality of political, infrastructural and institutional change. This edition also focuses on the all-encompassing, ever-evolving spectre of AI – what it is, what it wants and how it can be shaped meticulously into a force for good.

July 2024 - PharmaTimes

As the front cover so boldly suggests, this edition of PharmaTimes is at the ballot box! Indeed, we are pondering a future seems oddly elusive in spite of its alarming proximity! This is a very good reason for us to discuss the great themes of our time – who will take a country out of the debris of the last decade, what will become of our decrepit NHS, can we ever become best friends with AI, how can we ignite diversity throughout industry and, of course, how we can we make patient involvement vibe part of everyday pharma?

June 2024 - PharmaTimes

This issue is about the shaping, delivery and future of clinical trials – the exciting dawn of a new era for how therapies reach the marketplace. We cover the influence of digital, the radical shift in trial design and, above all, the need to incorporate patients at every stage. We’ve also got a review of our International Clinical Researcher of the Year bash – an unforgettable 25th edition of the enduring event. In addition, this issue looks at the influence of Florence Nightingale as an ace healthcare communicator, the future of unlicenced meds and the emerging involvement of AI across the life sciences.

May 2024 - PharmaTimes

This month we’re going places and – as our cover so boldly suggests – those places invite parity and equity. Women in pharma is a movement which not only yields a fair and more interesting pharmaverse, it ignites possibilities and propels performance. The edition of PharmaTimes you are about to peruse holds this reality aloft and parades it around our industry. We’ve also got a host of other features which demonstrate the rapid evolution of the life sciences including – the future of pharma, emerging novel therapies, taking on rare diseases and the continuing need to ensure a career in pharma is open to everyone.

April 2024 - PharmaTimes

Hope springs in this edition of PharmaTimes! By looking robots directly in the eye, we demystify how AI is influencing pharma and wider healthcare – as a force for good. Meanwhile, intrepid community pharmacists step out of the shadows and into bolder new arenas, helping to unshackle the NHS in the process. There are also captivating features on realising net-zero, campaign launches, men’s health and the evolving digital age. In addition, we continue to celebrate how new perspectives from women are igniting our industry and blazing a trail for the next generation. Yep, we’re living our best lives…

March 2024 - PharmaTimes

PharmaTimes ventures into modern, progressive and inclusive terrain! Our cover story looks at how diversity in clinical trials is evolving and what has to be done to ignite it. Meanwhile, we look at the future of pharma through a very modern lens, at a time when our industry is entering a sustained chapter of change. With this considered, there are also features on the compelling influence of women in pharma, the spectre of AI, the health climate crisis and why Star Trek could influence emerging MedTech. Yes, this magazine is boldly visiting new, unchartered dimensions!

January/February 2024 - PharmaTimes

We peruse the priorities for 2024 – innovation, partnerships and a focus on unmet clinical needs. Meanwhile, we focus on the healthcare horoscope of politics, tech, data, public health and the rise of the patient. Hop on for the ride as we ask how the NHS will be reconstructed, if the success in hepatitis C elimination can be repeated in HIV, why gene therapy challenges must be embraced and if we can realise the potential of real-world data throughout industry.

December 2023 - PharmaTimes

The bells are ringing out for the final, triumphant edition of PharmaTimes in the year two thousand and twenty-three! And it’s a cracker, as our front cover so humbly suggests. This edition is about reflections and prophecies, as well as the present and its myriad politics.

November 2023 - PharmaTimes

Once again PharmaTimes brings you the complete vista, the total panorama of the healthcare and pharmaceutical metropoli (new word siren!). We begin at the beginning – and that beginning is the future – and that future is now. With that considered we look at how doctors are high-fiving AI, how data is transforming treatments and how digital is igniting clinical trials. We've also got captivating and compelling content on why vaccines are evolving, the challenges of treating rare disease and the nuances of taking a Nordic approach. Changing the narrative of epilepsy and taking a different perspective on dementia completes a formidable line up.

October 2023 - PharmaTimes

New PharmaTimes is out now and on the campaign trail! With an eye on the general election, we look at which party can get our health service our of intensive care and into the arena of functionality. Yes, this month’s tome is all about positive (and desperately needed) change! We also focus of the inseparable connection between mental health and physical conditions. In addition, tech, AI and data will take us on a magical mystery tour of possibilities and potential throughout the pharmaverse. Meanwhile, the challenges of clinical trial redesign, personalised healthcare and precision medicine complete all-encompassing manifesto.